Filing Flows › Comparisons › IBO vs TLPH
Impact Biomedical vs Talphera: IBO and TLPH compared
Impact Biomedical is the larger company: $3K of revenue in its latest quarter (Q2 2026) against $1K for Talphera (Q3 2025).
Where the money goes: IBO and TLPH
Impact Biomedical (IBO) · Q2 2026
Impact Biomedical, Q2 2026: revenue $3K (-57% year over year), net loss $700K, operating cash flow $470K. The chart follows the revenue to costs, profit and cash.
Talphera (TLPH) · Q3 2025
Talphera, Q3 2025: revenue $1K, net loss $4.4M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Impact Biomedical (IBO) | Talphera (TLPH) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2025 |
| Revenue | $3K | $1K |
| Revenue growth, Y/Y | -57% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$700K | −$4.4M |
| Operating cash flow | $470K | −$2.5M |
Questions
Which is bigger, Impact Biomedical or Talphera?
Impact Biomedical is the larger company: $3K of revenue in its latest quarter (Q2 2026) against $1K for Talphera (Q3 2025).
More: Impact Biomedical earnings · how Impact Biomedical makes money · Talphera earnings · how Talphera makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 7, 2026; 10-Q filed Nov 12, 2025). Fiscal quarters can end on different dates. Not investment advice.